CN116574014A - Preparation method of zolmitriptan intermediate - Google Patents
Preparation method of zolmitriptan intermediate Download PDFInfo
- Publication number
- CN116574014A CN116574014A CN202310613940.7A CN202310613940A CN116574014A CN 116574014 A CN116574014 A CN 116574014A CN 202310613940 A CN202310613940 A CN 202310613940A CN 116574014 A CN116574014 A CN 116574014A
- Authority
- CN
- China
- Prior art keywords
- phenylalanine
- nitro
- solvent
- zolmitriptan
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 title claims abstract description 39
- 229960001360 zolmitriptan Drugs 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 238000006243 chemical reaction Methods 0.000 claims abstract description 74
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 64
- 238000000034 method Methods 0.000 claims abstract description 64
- GTVVZTAFGPQSPC-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(4-nitrophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-QMMMGPOBSA-N 0.000 claims abstract description 61
- 239000002904 solvent Substances 0.000 claims abstract description 59
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims abstract description 37
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229960005190 phenylalanine Drugs 0.000 claims abstract description 32
- 229950005223 levamfetamine Drugs 0.000 claims abstract description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229910017604 nitric acid Inorganic materials 0.000 claims abstract description 24
- 238000006396 nitration reaction Methods 0.000 claims abstract description 19
- 230000001546 nitrifying effect Effects 0.000 claims abstract description 12
- 238000006722 reduction reaction Methods 0.000 claims abstract description 10
- 239000007864 aqueous solution Substances 0.000 claims abstract description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 39
- 230000008569 process Effects 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 23
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 20
- 239000011591 potassium Substances 0.000 claims description 20
- 229910052700 potassium Inorganic materials 0.000 claims description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 18
- 239000003638 chemical reducing agent Substances 0.000 claims description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 10
- 239000002841 Lewis acid Substances 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 10
- 229910052708 sodium Inorganic materials 0.000 claims description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 9
- 230000035484 reaction time Effects 0.000 claims description 7
- 239000012279 sodium borohydride Substances 0.000 claims description 7
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 3
- 125000003944 tolyl group Chemical group 0.000 claims description 3
- 239000000047 product Substances 0.000 abstract description 55
- 239000002253 acid Substances 0.000 abstract description 15
- 239000002699 waste material Substances 0.000 abstract description 14
- 239000007788 liquid Substances 0.000 abstract description 13
- 238000000746 purification Methods 0.000 abstract description 10
- 230000007613 environmental effect Effects 0.000 abstract description 7
- 239000012535 impurity Substances 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 239000006227 byproduct Substances 0.000 abstract description 4
- 238000005265 energy consumption Methods 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 description 24
- 235000019441 ethanol Nutrition 0.000 description 18
- 239000007787 solid Substances 0.000 description 17
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 229940125782 compound 2 Drugs 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- 238000001816 cooling Methods 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000005457 ice water Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 239000012295 chemical reaction liquid Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 6
- -1 Lewis acid boron trifluoride Chemical class 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000032050 esterification Effects 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 150000007517 lewis acids Chemical class 0.000 description 4
- 206010027599 migraine Diseases 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000011592 zinc chloride Substances 0.000 description 3
- 235000005074 zinc chloride Nutrition 0.000 description 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- PCLGMKWXPXAGEO-QMMMGPOBSA-N (2s)-2-amino-3-(4-nitrophenyl)propan-1-ol Chemical compound OC[C@@H](N)CC1=CC=C([N+]([O-])=O)C=C1 PCLGMKWXPXAGEO-QMMMGPOBSA-N 0.000 description 1
- UGMTUMDXTQOCKC-UHFFFAOYSA-N 1-(4-nitrophenyl)propan-1-ol Chemical compound CCC(O)C1=CC=C([N+]([O-])=O)C=C1 UGMTUMDXTQOCKC-UHFFFAOYSA-N 0.000 description 1
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- DOQLCJMCQWQQHK-UHFFFAOYSA-N 4-chlorobutanal Chemical compound ClCCCC=O DOQLCJMCQWQQHK-UHFFFAOYSA-N 0.000 description 1
- 102000035038 5-HT1 receptors Human genes 0.000 description 1
- 108091005478 5-HT1 receptors Proteins 0.000 description 1
- 102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 description 1
- 101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010003791 Aura Diseases 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000007824 aliphatic compounds Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- GUJMUFSJFDQBJC-UHFFFAOYSA-N bis(trichloromethyl) carbonate;carbonyl dichloride Chemical compound ClC(Cl)=O.ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl GUJMUFSJFDQBJC-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Substances FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007345 electrophilic aromatic substitution reaction Methods 0.000 description 1
- 238000007336 electrophilic substitution reaction Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000002920 hazardous waste Substances 0.000 description 1
- 230000017525 heat dissipation Effects 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000010714 indole synthesis reaction Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- BRWZPVRDOUWXKE-UHFFFAOYSA-N methylsulfanylmethane;trifluoroborane Chemical compound CSC.FB(F)F BRWZPVRDOUWXKE-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- ULSDMUVEXKOYBU-ZDUSSCGKSA-N zolmitriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C[C@H]1COC(=O)N1 ULSDMUVEXKOYBU-ZDUSSCGKSA-N 0.000 description 1
- 229940003675 zomig Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention provides a preparation method of an zolmitriptan intermediate, which comprises the following steps: the method comprises the steps of taking sulfuric acid aqueous solution as a solvent, taking concentrated nitric acid or fuming nitric acid as a nitrifying reagent, and performing nitration reaction on L-phenylalanine in a microchannel reactor to obtain 4-nitro-L-phenylalanine. The 4-nitro-L-phenylalanine is subjected to reduction reaction to prepare the 4-nitro-L-amphetamine alcohol. The method for preparing 4-nitro-L-phenylalanine reduces the consumption of concentrated sulfuric acid or mixed acid, reduces the cost, and is more beneficial to environmental protection; the reaction condition is mild, the realization and control are easy, the preparation period is short, the purification is simple, the energy consumption is low, and the cost is further reduced; good reaction selectivity, less byproducts and high yield and purity of target products. The method for preparing 4-nitro-L-amphetamine alcohol is safe, environment-friendly, reduces the generation of waste liquid and has low cost; few impurities, simple purification steps and high yield and purity of the target product.
Description
Technical Field
The invention belongs to the field of pharmaceutical chemicals, and particularly relates to a preparation method of an zolmitriptan intermediate.
Background
Zolmitriptan (Zolmitriptan), chemical name: (S) -4- [ [3- [2- (dimethylamino) ethyl ]]Indol-5-yl]Methyl group]-2-oxazolidinones of formula C 16 H 21 N 3 O 2 Molecular weight 287.36, having a chemical structure represented by formula 1:
zolmitriptan (Zolmitriptan) was first developed by Wellcom corporation, england, for the acute treatment of moderate and severe migraine with or without symptoms of aura. Zolmitriptan patent (US 5466699) was first obtained on 12 months of 1991. And then assigned to UK Jielikang (Zenece) and sold for the first time in the Federal of English in 3 months 1997 under the trade name Zomig. The FDA approved 11 th 1997 for market in the united states. And then sold in member countries of the European Union, such as Germany, netherlands, denmark, etc. The dosage forms on the market include tablets, dispersible tablets, buccal tablets, capsules and the like.
Zolmitriptan is a novel, efficient and specific drug for treating acute migraine, is a highly selective 5-HT1B/1D receptor agonist, and can relieve the attack of migraine by activating 5-HT1 receptor to cause vasoconstriction and inhibit release of neuropeptides. The pharmacological study results showed that: zolmitriptan not only can control peripheral blood flow of brain, but also can act on pain center of brain, thereby playing a role in treating migraine.
At present, a plurality of patents and documents at home and abroad report on a synthesis method of zolmitriptan. The existing zolmitriptan has more synthetic routes, and most of the zolmitriptan takes L-phenylalanine or 4-nitro-L-phenylalanine as a starting material, and the target compound is obtained through 7-9 steps of reaction. The relevant synthetic routes are summarized as follows:
the synthesis route I is as follows:
this route starts from 4-nitro-L-phenylalanine, first with MeOH and SOCl 2 Reacting to form ester, and then passing through NaBH 4 Reducing to obtain corresponding alcohol; closing the ring of alcohol and phosgene under alkaline conditions to obtain a compound 5; compound 5 via H 2 Reduction of nitro group by Pd/C to give Compound 6; diazotizing the compound 6 to obtain a compound 7; the compound 7 and 4-chlorobutyraldehyde glycol undergo a rearrangement reaction to generate an indole cycloamino compound, and the compound and NaBH 3 CN/HCHO reaction to obtain target compound 1.
The synthesis route II is as follows:
the process uses L-phenylalanine as a starting material, and the L-phenylalanine and nitric acid are subjected to nitration reaction under the catalysis of sulfuric acid to generate a compound 2. Compound 2 is catalyzed by Lewis acid boron trifluoride and an expensive boron trifluoride dimethyl sulfide reaction is used to produce compound 4. Compound 4 is cyclized with phosgene to obtain compound 5. And then go through H 2 Reduction and diazotization of/Pd/C gives compound 7. The compound 7 and 3-cyano diethyl acetal undergo condensation reaction, then cyclize under the action of p-toluenesulfonic acid to generate indole compound, finally in H 2 Reacting with dimethylamine under the catalysis of Pd/C to generate the target compound 1.
The synthesis route III:
the route uses L-phenylalanine as a starting material, and comprises the steps of first preparing a solution in HNO 3 And H is 2 SO 4 Para-nitration under the action of (2) to give compound (2) with MeOH and SOCl 2 The reaction gives an esterified product 3, which is prepared by NaBH 4 Reduction to obtain hydroxyBase compound 4. And (3) carrying out cyclization reaction with solid phosgene (triphosgene) to obtain a compound 5. Reducing nitro group by hydrazine hydrate to obtain a compound 6; and diazotizing to obtain the compound 7. The target compound 1 is prepared by the Fischer (Fischer) indole synthesis reaction of the compound 7 and 4- (dimethylamino) butyraldehyde diethanol.
In the synthetic route, the intermediate compound 2 and the intermediate compound 4 with the same structure are prepared by different methods or conditions; the compound is an important structural fragment for preparing zolmitriptan and is an important intermediate for preparing zolmitriptan.
However, the method for preparing the intermediate compound 2, namely 4-nitro-L-phenylalanine has the advantages of large consumption of concentrated sulfuric acid and concentrated nitric acid, large waste acid production, environmental protection and high cost; the reaction temperature is lower, the reaction condition is harsh, the energy consumption is high, the reaction period is long, and the cost is further increased; the nitration reaction has poor selectivity, more ortho-position byproducts, complicated purification steps and low yield and purity of target products. The method for preparing the intermediate compound 4, namely 4-nitro-L-amphetamine alcohol, adopts a method of firstly esterifying and then reducing the nitrified L-phenylalanine, the esterification of amino acid is generally hydrochloric acid or thionyl chloride for catalytic esterification, the two are strong acid and volatile, the equipment and personnel are extremely unfriendly, more acid waste liquid is generated in the post-treatment, a large amount of dangerous waste is generated, and the requirements of current green production are not met; and a large amount of impurities are generated, and the yield and purity of the target product are low. The prior art also reports a method for reducing alpha-amino acid into alpha-amino alcohol in one step, but the reaction degree of a target product is poor, the yield is lower, the impurities are more, and the purity is lower; the product yield is further reduced by purifying for a plurality of times to obtain the product meeting the requirements, the production cost of the product is increased, a large amount of solvent is used by purifying for a plurality of times, the treatment pressure of the organic solvent is further increased, and the environmental protection and the waste liquid treatment are not facilitated.
The present invention has been made to solve the above-described problems.
Disclosure of Invention
Aiming at the defects existing in the prior art, the invention provides a preparation method of an zolmitriptan intermediate. The method for preparing the intermediate compound 2, namely 4-nitro-L-phenylalanine, reduces the consumption of concentrated sulfuric acid or mixed acid (concentrated sulfuric acid and concentrated nitric acid), reduces the production of strong acid waste liquid, reduces the cost, and is more beneficial to environmental protection; the reaction condition is mild, the realization and control are easy, the preparation period is short, the purification is simple, the energy consumption is low, and the cost is further reduced; good reaction selectivity, less byproducts and high yield and purity of target products. The method for preparing the intermediate compound 4, namely 4-nitro-L-amphetamine alcohol, is safe, environment-friendly, reduces the generation of waste liquid and has low cost; few impurities, simple purification steps and high yield and purity of the target product.
The technical scheme of the invention is as follows:
a preparation method of a zolmitriptan intermediate 4-nitro-L-phenylalanine comprises the following steps: the method comprises the steps of taking sulfuric acid aqueous solution as a solvent, taking concentrated nitric acid or fuming nitric acid as a nitrifying reagent, and performing nitration reaction on L-phenylalanine in a microchannel reactor to obtain 4-nitro-L-phenylalanine.
According to the invention, the mass fraction of the aqueous sulfuric acid solution is preferably 75 to 98%, preferably 75 to 85%.
According to the invention, the mass fraction of nitric acid in the concentrated nitric acid or fuming nitric acid is preferably 64-97%.
According to the invention, the mass ratio of the aqueous sulfuric acid solution to the L-phenylalanine is preferably 1-5:1, preferably 1-2:1.
According to the invention, the molar ratio of the nitrifying agent concentrated nitric acid or fuming nitric acid to L-phenylalanine is 1-2:1; preferably 1:1.
According to the invention, the nitration temperature is preferably from-5 to 30℃and preferably from 5 to 20 ℃.
According to the invention, the nitration time is preferably from 20 seconds to 300 seconds, preferably from 28 seconds to 60 seconds.
According to the invention, the microchannel reactor is commercially available.
According to the present invention, a preferred method for producing 4-nitro-L-phenylalanine comprises the steps of: dissolving L-phenylalanine in sulfuric acid aqueous solution to obtain L-phenylalanine solution; and respectively and simultaneously introducing the L-phenylalanine solution and concentrated nitric acid or fuming nitric acid into a micro-channel reactor, and performing nitration reaction on the L-phenylalanine to obtain the zolmitriptan intermediate 4-nitro-L-phenylalanine.
Preferably, the flow rate of the L-phenylalanine solution is 0.5-2ml/min; the flow rate of the concentrated nitric acid or fuming nitric acid is 0.3-1ml/min; preferably, the flow rate of the L-phenylalanine solution is 1ml/min; the flow rate of the concentrated nitric acid or fuming nitric acid is 0.6ml/min.
According to the present invention, preferably, the method for post-treating the reaction liquid obtained by the nitration reaction comprises the steps of: and (3) introducing the reaction solution into water with the temperature below 10 ℃, fully and uniformly mixing, and filtering, washing and drying to obtain the 4-nitro-L-phenylalanine.
A preparation method of a zolmitriptan intermediate 4-nitro-L-amphetamine alcohol comprises the following steps: 4-nitro-L-phenylpropanol (chemical name, (S) -2-amino-3- (4-nitrophenyl) propanol) is prepared by reduction reaction of the obtained 4-nitro-L-phenylalanine (chemical name, (S) -2-amino-3- (4-nitrophenyl) propionic acid) in a solvent in the presence of a reducing agent.
According to a preferred embodiment of the invention, the solvent consists of solvent a and solvent B;
the solvent A is one or the combination of more than two of tetrahydrofuran, methyltetrahydrofuran, methanol or ethanol; preferably, the solvent A is tetrahydrofuran;
the solvent B is one or the combination of more than two of toluene, dimethylbenzene or dioxane; preferably, the solvent B is toluene;
the volume ratio of the solvent A to the solvent B is 1:0.5-10, preferably 1:1-4.
Preferably, solvent A and solvent B are added prior to the addition of 4-nitro-L-phenylalanine, or solvent A is added prior to the addition of 4-nitro-L-phenylalanine and solvent B is added after the addition of 4-nitro-L-phenylalanine.
According to the invention, the ratio of the mass of 4-nitro-L-phenylalanine to the volume of the solvent is preferably 0.01-0.1g/mL.
According to a preferred embodiment of the invention, the reducing agent is sodium borohydride, potassium borohydride, sodium borohydride-wayEasily-basic acid, potassium borohydride-Lewis acid, potassium borohydride-iodine, sodium borohydride-H 2 SO 4 Or potassium borohydride-H 2 SO 4 One of them.
Preferably, the lewis acid is one or a combination of more than two of aluminum chloride, zinc chloride, lithium chloride, nickel chloride, palladium chloride or calcium chloride.
Preferably, the molar ratio of sodium borohydride or potassium borohydride to Lewis acid in the sodium borohydride-Lewis acid or potassium borohydride-Lewis acid is 1-6:1, preferably 2-4:1, more preferably 2:1; in the potassium borohydride-iodine and the sodium borohydride-iodine, the molar ratio of the sodium borohydride or the potassium borohydride to the iodine is 1-3:1, preferably 1-1.5:1, more preferably 1.1:1; sodium borohydride-H 2 SO 4 Potassium borohydride-H 2 SO 4 In which sodium or potassium borohydride and H 2 SO 4 The molar ratio of (2) is 1-3:1, preferably 1-1.5:1, more preferably 1.1:1.
According to the invention, the molar ratio of 4-nitro-L-phenylalanine to reducing agent is preferably 1:1-8.
According to the present invention, preferably, 4-nitro-L-phenylalanine may be added to the reaction system at one time or in divided portions.
According to the present invention, 4-nitro-L-phenylalanine is preferably produced as described above.
According to the invention, the preparation method of the zolmitriptan intermediate 4-nitro-L-amphetamine comprises the following steps:
adding a reducing agent and 4-nitro-L-phenylalanine into the solvent A; then adding a solvent B, and reacting to obtain an zolmitriptan intermediate 4-nitro-L-amphetamine alcohol;
or, adding a reducing agent into the solvent A, and adding 4-nitro-L-phenylalanine in batches; then adding a solvent B, and reacting to obtain the zolmitriptan intermediate 4-nitro-L-amphetamine.
Preferably, the step of heating and refluxing is further included after the reducing agent and the 4-nitro-L-phenylalanine are added into the solvent A; the heating reflux reaction temperature is 60-66 ℃ and the reaction time is 1-5h.
Preferably, the method further comprises the step of heating and refluxing before adding the 4-nitro-L-phenylalanine in batches; alternatively, the method may further comprise a step of heating and refluxing after the 4-nitro-L-phenylalanine is added in portions; the heating reflux reaction temperature is 60-66 ℃ and the reaction time is 1-5h.
Preferably, the reaction temperature after adding the solvent B is 66-140 ℃, preferably 80-100 ℃; the reaction time is 2 to 24 hours, preferably 6 to 12 hours.
Preferably, when 4-nitro-L-phenylalanine is added in portions, it is added in 2-4 portions and is added over 5-15 minutes.
According to the present invention, a method for post-treating a reaction solution obtained by reducing 4-nitro-L-phenylalanine comprises the steps of:
stirring and cooling the reaction liquid to room temperature, dripping water for quenching, filtering, extracting the water phase with toluene or ethyl acetate, merging the organic phases, drying the organic phases through anhydrous magnesium sulfate or anhydrous sodium sulfate, filtering, and concentrating under reduced pressure until the organic phases are dried to obtain 4-nitro-L-amphetamine;
or, stirring and cooling the reaction liquid to room temperature, cooling the reaction liquid to 0-10 ℃ by ice water, and filtering to remove solids; dropwise adding a sodium hydroxide aqueous solution into the obtained filtrate, and filtering to remove generated solids; separating the obtained filtrate, extracting the water phase with toluene or ethyl acetate, mixing the organic layers, drying the organic phase with anhydrous magnesium sulfate or anhydrous sodium sulfate, filtering, concentrating the filtrate under reduced pressure to dryness to obtain 4-nitro-L-amphetamine;
or, stirring and cooling the reaction liquid to room temperature, cooling the reaction liquid to 0-10 ℃ by ice water, and filtering to remove solids; washing the obtained filtrate with water, separating the liquid, and concentrating the organic layer under reduced pressure to dryness to obtain the 4-nitro-L-amphetamine alcohol.
The synthetic route of the invention is as follows:
the invention has the technical characteristics that:
preparation of 4-nitro-L-phenylalanine:
through research improvement, the invention adjusts the concentration and the dosage of the concentrated sulfuric acid of the solvent, reduces the dosage of the concentrated sulfuric acid or the mixed acid (the concentrated sulfuric acid and the concentrated nitric acid) of the solvent, reduces the dosage from 3-4 times of the conventional dosage to 1-2 times of the conventional dosage, avoids generating a large amount of strongly acidic waste liquid, is environment-friendly and has low cost.
Meanwhile, the use of the nitrifying reagent is reduced through optimizing the proportion, the molar quantity of nitric acid for nitrifying is reduced to 1:1 through adopting a microchannel reactor, the nitrifying reaction temperature is controlled stably and well, the reaction is carried out at a higher, mild and easily-realized reaction temperature, the reaction period is short, meanwhile, the risk of out-of-control of the nitrifying temperature can be completely controlled, and the reaction is safe, green and environment-friendly, and the cost is further reduced.
After the process is improved, the isomer of the nitrified product is effectively controlled, the nitrified product prepared by the process reported in the literature contains about 10% -20% of o-nitro isomer, after the process is improved, the para-nitrified product (namely 4-nitro-L-phenylalanine) with high purity can be obtained by using the method of the invention without purification or simple post-treatment, the reaction selectivity is good, the purity of the product can reach more than 97%, and the isomer is greatly reduced to within 3.5%. The purity can be directly used for reaction without further refining.
The highest nitration reaction yield of L-phenylalanine is 68% in Zymtriptan synthesis process research of Zhongmiatriptan university paper, and other prior documents report that the yield is not more than 60%. The improved process of the invention improves the production efficiency and the yield of the nitrified product, and the yield is improved to more than 88% from less than 60% due to avoiding the production of nitrified isomers, thereby shortening the production time, reducing the production cost and reducing the discharge and the treatment of a large amount of acid hazardous wastes.
The nitration reaction is a reaction process of introducing nitro into organic compound molecules, the mechanism of the reaction process is mainly divided into two types, the nitration of aliphatic compounds is generally realized through free radical processes, the reaction processes are complex, and different systems can be different; the reaction history is typical of electrophilic substitution reactions for aromatic compounds. In the reaction, the hydroxyl group of nitric acid is protonated and dehydrated to form nitroxyl cation (NO 2 And then carrying out electrophilic aromatic substitution reaction with benzene ring, and removing one molecule of hydrogen ions. The common nitrifying reagent is concentrated nitric acid, fuming nitric acid, concentrated sulfuric acid and mixed acid of concentrated sulfuric acid and nitric acid are common dehydrating agents, and the existence of strong acid materials has strict requirements on reaction equipment. The heat release enthalpy in the nitration reaction is increased, the strong heat release reaction is realized, the vast majority of reaction heat exceeds 600J/g, the reaction is very severe, and the material flushing or explosion accident is easily caused by out-of-control, so the nitration reaction is also classified as a dangerous supervision process. In order to control the reaction rate, heat generated by the reaction is timely led out, the nitration reaction needs to be cooled and controlled, and the temperature is difficult to control and also can not generate nitrated isomer or polynitro products, so that the purity of the products is reduced, and the cost is increased. According to the invention, after the microchannel reactor is used, the contact time and concentration of the nitrifying reagent and the reaction raw materials can be effectively controlled, the heat dissipation area is increased, and the reacted product is led out and quenched in time; the invention effectively inhibits the occurrence of side reaction and improves the selectivity and conversion rate of the reaction by adopting the micro-channel reactor. And meanwhile, the amount of materials for contact reaction is reduced, so that the exothermic heat of the reaction is effectively controlled, and the reaction is safer and more controllable.
Preparation of 4-nitro-L-amphetamine alcohol:
the method for preparing 4-nitro-L-amphetamine from the nitrified 4-nitro-L-phenylalanine is summarized in domestic and foreign literature reports, the method for preparing 4-nitro-L-amphetamine by esterification and then reduction of the nitrified 4-nitro-L-phenylalanine is adopted, the esterification of amino acid is generally hydrochloric acid or thionyl chloride for catalytic esterification, the two are strong acid and volatile, the method is extremely unfriendly to equipment and personnel, more acid waste liquid is generated by post-treatment, a large amount of dangerous waste is generated, and the method does not meet the requirements of current green production.
According to the literature, the two-step yield of 4-nitro-L-amphetamine alcohol prepared in WO9118897A1 is only 37.0%; the two-step yield disclosed in Zaomitriptan synthesis and technological improvement published by Zhangling, quhaole and Zhou Shujing is about 79.4%, which is the highest yield in the prior art. But prepared by using the process disclosed in "synthesis of zolmitriptan and process improvement", the reported method was not repeated, the single step yield of 4-nitro-L-amphetamine was found to be only 40.2%, and the purity of 4-nitro-L-amphetamine was very low due to the large amount of sodium hydroxide solution used in the reduction process to neutralize the salt of 4-nitro-L-phenylalanine in the previous step; the yield of the preparation of 4-nitro-L-amphetamine alcohol by the two-step method is only about 55-67%.
In the preparation of 4-nitro-L-amphetamine, the use of sodium borohydride/potassium borohydride+Lewis acid to reduce nitrated L-phenylalanine to nitro-L-amphetamine in one step has not been reported in literature.
The inventors have tried to apply various reduction methods to the preparation of alpha-amino acid to alpha-amino alcohol by one-step reduction, and found in experiments that according to the literature preparation, the reaction time is prolonged to 3 days, the reaction is still not completed, the product yield is very low, only about 40%, and a large amount of unreacted materials are contained in the obtained product, so that the product yield is low and the quality is poor. In order to obtain the product meeting the requirements, multiple purifications are needed, the product yield is further reduced, the product production cost is increased, multiple purifications also cause the use of a large amount of solvents, the treatment pressure of the organic solvent is further increased, and the environmental protection and the waste liquid treatment are not facilitated.
According to the invention, a high boiling point solvent toluene or xylene and the like are added when 4-nitro-L-phenylalanine is reduced by a one-step method, so that the reaction temperature is increased, the reaction energy is further increased, the reaction is completely carried out in a short time, all 4-nitro-L-phenylalanine is reduced into 4-nitro-L-amphetamol by one step, the conversion rate is greatly increased, and the yield is increased to 80-90%. Meanwhile, as the preparation of the ester is not carried out any more, the use of strong acid volatile materials such as HCl, sulfoxide chloride and the like is avoided, the influence on the environment is reduced, the equipment is corroded, the method is friendly to operators, the production of waste liquid is reduced, the environmental protection is facilitated, and the concept of green chemistry is practiced.
In the preparation, it is found that when simple tetrahydrofuran or alcohols are used as solvents and a sodium borohydride/potassium borohydride+Lewis acid system is used for reduction, the 4-nitro-L-phenylalanine has a low reaction degree and cannot be completely reacted, and a large amount of unreacted 4-nitro-L-phenylalanine residues cause the 4-nitro-L-amphetamine to have a low yield which is less than 40%. The invention improves the process, adds a proper amount of toluene or dimethylbenzene in the reaction system after the initial stage of the reaction or the reaction is carried out for a period of time, and moderately increases the reaction temperature; after the continuous reaction is carried out for a period of time, the 4-nitro-L-phenylalanine is completely reacted, and the yield of the 4-nitro-L-amphetamine is improved to 80-90%.
The invention has the following beneficial effects:
1. the preparation method of 4-nitro-L-phenylalanine reduces the consumption of concentrated sulfuric acid and nitrifying reagent by using the microchannel reactor, reduces the production of strong acid waste liquid, reduces the cost and is more beneficial to environmental protection; the reaction condition is mild, the realization and control are easy, the preparation period is short, the purification is simple, the energy consumption is low, and the cost is further reduced; good reaction selectivity, less byproducts, high yield and purity of target products, and suitability for industrial production.
2. In the preparation of the 4-nitro-L-amphetamine alcohol, the two-step reaction of esterifying and reducing the alcohol is simplified into one step, so that the preparation time is shortened; the method is safe, green and environment-friendly, reduces the generation of three wastes (especially the neutralization and emission of hydrochloric acid gas) and has low cost; few impurities, simple purification steps, high yield and purity of target products, and suitability for industrial production.
Drawings
FIG. 1 is an HPLC chart of the product prepared in example 1;
FIG. 2 is an HPLC plot of the product prepared in example 2;
FIG. 3 is an HPLC plot of the product prepared in example 3;
FIG. 4 is an HPLC plot of the product prepared in example 4;
FIG. 5 is an HPLC plot of the product prepared in example 10;
FIG. 6 is an MS spectrum of the product prepared in example 10;
FIG. 7 is a product of example 10 1 HNMR nuclear magnetic patterns;
FIG. 8 is an HPLC plot of the product prepared in example 11;
FIG. 9 is an HPLC plot of the product prepared in example 14;
FIG. 10 is an HPLC plot of the product prepared in example 18;
FIG. 11 is an HPLC plot of the product prepared in example 19;
FIG. 12 is an HPLC plot of the product prepared in example 20;
FIG. 13 is an HPLC plot of the product prepared in comparative example 1;
FIG. 14 is an HPLC plot of the product prepared in comparative example 3.
Detailed Description
The present invention is further illustrated by the following specific examples, but it should be understood that these examples are for the purpose of more detailed description only and should not be construed as limiting the invention in any way.
In the examples, the reagents used, as such are commercially available without specific description; the methods used, unless otherwise specified, are all prior art.
The micro-channel reactor in the embodiment is an existing commercial device and is matched with a double-plunger high-pressure constant-flow infusion pump for a multi-module micro-reactor unit.
Examples 1 to 6
Compound 2: preparation of 4-nitro-L-phenylalanine, channel flow rate investigation
50g of concentrated sulfuric acid (98 wt.%) were added dropwise to 10g of water under stirring and cooled with ice water, and the mixture was cooled to room temperature. 60g (0.36 mol) of L-phenylalanine was slowly added thereto with continued cooling, and stirred until the solid was dissolved, to obtain an L-phenylalanine solution. The L-phenylalanine solution (at 20 ℃ C.) was introduced into the reactor through the channel 1 at a set flow rate of 1ml/min.
Simultaneously, 34.8g (0.36 mol) of concentrated nitric acid (65 wt%) at 20 ℃ is fed into the micro-channel reactor through the channel 2, and the flow rate is set to be 0.6ml/min; the temperature of the reaction cavity of the micro-channel is controlled to be 5-10 ℃, and the mixing reaction time in the micro-channel reactor is kept to be 28 seconds. After the reaction, the material liquid is pumped into water which is pre-cooled to 0 ℃, stirred for 30min, filtered, washed with water until the pH is about 7, and dried at 70 ℃ to obtain 71.6g of yellow solid with the yield of 93.8%.
The HPLC chart of the product obtained in this example is shown in FIG. 1, and the purity of the target product is 97.29% and the isomer content is 2.20%.
According to the same method, the experimental results of the compound 2 (4-nitro-L-phenylalanine) prepared by setting different flow rates are as follows:
examples | Channel 1 | Channel 2 | Feeding amount | Yield of | Yield is good | Purity of | Isomers of | Remarks |
1 | 1ml/min | 0.6ml/min | 60g | 71.6g | 93.8% | 97.29% | 2.20% | FIG. 1 |
2 | 1ml/min | 0.3ml/min | 60g | 70.3g | 92.1% | 97.60% | 1.80% | FIG. 2 |
3 | 1ml/min | 0.8ml/min | 60g | 68.9g | 90.3% | 96.61% | 2.81% | FIG. 3 |
4 | 1ml/min | 1ml/min | 60g | 69.1g | 90.5% | 96.10% | 3.59% | FIG. 4 |
5 | 0.5ml/min | 0.6ml/min | 60g | 67.5g | 88.4% | 96.14% | 2.12% | - |
6 | 2ml/min | 0.6ml/min | 60g | 67.9g | 88.9% | 95.89% | 2.05% | - |
From the above examples, the nitrified product prepared by the method of the present invention has a high yield of more than 85% when the flow rate of the L-phenylalanine solution (channel 1) is 0.5 to 2ml/min and the flow rate of the concentrated nitric acid (channel 2) is 0.3 to 1ml/min.
Concentrated nitric acid (lane 2) sulfuric acid is preferably 0.6ml/min, and L-phenylalanine (lane 1) sulfuric acid is preferably 1ml/min.
Examples 7 to 9
Compound 2: preparation of 4-nitro-L-phenylalanine
60g of concentrated sulfuric acid (98 wt.%) were added dropwise to 16ml of water under stirring and cooled with ice water, and the mixture was cooled to room temperature. 60g (0.36 mol) of L-phenylalanine was slowly added under ice water cooling, and stirred until the solid was dissolved, to obtain an L-phenylalanine solution. The L-phenylalanine solution was fed into the microchannel reactor through channel 1 at a flow rate of 1ml/min.
Simultaneously, 34.8g (0.36 mol) of concentrated nitric acid (65 wt%) was introduced into the microchannel reactor through channel 2 at a flow rate of 0.6ml/min; the temperature of the reaction chamber of the micro-channel is controlled, and the reaction time in the micro-channel reactor is kept to be 60 seconds. After the reaction, pumping the material liquid into water which is precooled to 0 ℃, stirring for 30min, filtering, washing with water to pH of about 7, and drying the solid at 60 ℃ to obtain yellow solid.
According to the same method, the experimental results of the compound 2 (4-nitro-L-phenylalanine) prepared by setting different temperatures are as follows:
the examples show that the reaction can produce the required product at the reaction temperature of 5-20 ℃.
Comparative example 1
Reference "synthesis and Process improvement of zolmitriptan" prepares 4-nitro-L-phenylalanine.
Compound 2: preparation of 4-nitro-L-phenylalanine
In the low-temperature cooling circulation bath, 21.2g of water is added into a reaction bottle, 133.6g of concentrated sulfuric acid is added dropwise under the condition of cooling, and 50g of L-phenylalanine is added continuously under the condition of cooling. And (3) dropwise adding a mixed solution of 12.5ml of fuming nitric acid and 12.5ml of concentrated sulfuric acid, wherein the temperature is controlled to be not more than 20 ℃ in the dropwise adding process, and the temperature is raised to 30 ℃ after the dropwise adding, so that the reaction is carried out for 3 hours.
The reaction solution was poured into 500ml of ice water, the pH of the solution was adjusted to about 7 by adding ammonia water, suction filtration was performed, and the solid was washed with 30ml of water to obtain 47.3g of a yellow solid, and the yield was 74.3%.
The HPLC chart of the product obtained in this comparative example is shown in FIG. 13, and the purity of the target product is 85.19% and the isomer content is 11.14%.
The preparation method of the invention has obvious advantages compared with the preparation results of literature methods, and the following table is shown in detail:
conclusion: compared with the conventional kettle-type nitration method, the novel method for preparing the product has the advantages of high yield, high purity of the target product, good isomer control, higher safety, higher efficiency and lower cost.
Examples 10 to 20
Compound 4: preparation of 4-nitro-L-amphetamine alcohol
200ml of tetrahydrofuran (solvent A) and 34.0g (0.25 mol) of zinc chloride (reducing agent 1) were added to a reaction flask, 27.0g (0.5 mol) of potassium borohydride (reducing agent 2) was added with stirring, and the mixture was heated to reflux (60℃to 66 ℃) for 2 hours. The heating was turned off and the temperature was slightly lowered to 60℃and 21.0g (0.1 mol) of 4-nitro-L-phenylalanine (Compound 2) prepared in the method of example 2 was added to the reaction mixture in 3 batches, each batch of about 7g, and the addition was completed for about 10 minutes, preventing the addition from being carried out by a vigorous reaction.
After the addition, 200ml of toluene (solvent B) was added to the reaction mixture and heated to 85℃and the reaction was continued for 10 hours with heat preservation, and the heating was stopped. The reaction solution was cooled to room temperature with stirring, and then cooled to 0 to 10℃with ice water. Suction filtration to remove solids (if necessary with celite filtration). 150ml of 20wt% sodium hydroxide aqueous solution was slowly added dropwise thereto over a period of Bi Jiaoban min. Filtering, removing the generated solid again, and separating filtrate. The aqueous phase was extracted with toluene 50ml×3 times, and the organic layers were combined and dried over anhydrous magnesium sulfate. The drying agent was filtered and the organic layer was distilled to dryness to give 17.3g of orange solid in 88.3% yield.
The HPLC chart of the product obtained in this example is shown in FIG. 5, and the purity is 99.13%.
The mass spectrum of the obtained product is shown in FIG. 6, and the peak with mass-to-charge ratio m/z= 197.1 is compound 4 (C 9 H 12 N 2 O 3 Exact Mass:196.1 Molecular ion [ M+H ]] + Peak, compound 4 molecular weight correct; the nuclear magnetic pattern is shown in fig. 7, and the data are as follows: 1 H NMR(600MHz,DMSO,δ):1.36(s,2H,NH 2 ),2.50-2.57(m,1H,NCH),2.83-2.91(m,2H,ArCH 2 ),3.20-3.28(m,2H,OCH 2 ),4.67(s,1H,OH),7.50(d,J=9Hz,2H,ArH),8.15(dd,J=7.2Hz,2.4Hz,2H,ArH).
4-nitro-L-amphetamine was prepared according to the above method under different combinations of reducing agents, solvent combinations, etc., and the conditions not shown in the table are as described above, and the experimental results are shown in the table below. The yield and quality of the obtained target product are higher than those of the product prepared by the prior process method.
/>
* Remarks: the dimethylbenzene mainly comprises a mixture of 45-70wt% of m-xylene, 15-25wt% of p-xylene and 10-15wt% of o-xylene, and is commercially available.
As can be seen from the above table, the solvent A is one or more of tetrahydrofuran, methyltetrahydrofuran, methanol or ethanol, and the solvent B is one or more of toluene, xylene or dioxane, so that a sample meeting the requirements can be prepared. Solvent A is preferably tetrahydrofuran and solvent B is preferably toluene. The volume ratio of the solvent A to the solvent B is 1:0.5-10, preferably 1:1-4.
The reducing agent is sodium borohydride, potassium borohydride, sodium borohydride-Lewis acid, potassium borohydride-iodine, sodium borohydride-H 2 SO 4 Or potassium borohydride-H 2 SO 4 Can be used for preparing samples meeting the requirements.
Comparative examples 2 to 4
Compound 4: preparation of 4-nitro-L-amphetamine alcohol
200ml of the reaction solvent and 34.0g (0.25 mol) of zinc chloride were added to the reaction flask, 27.0g (0.5 mol) of potassium borohydride was added under stirring, and the mixture was heated to reflux (60℃to 66 ℃) for 2 hours. The heating was turned off and the temperature was slightly lowered to 60℃and 21.0g (0.1 mol) of 4-nitro-L-phenylalanine (Compound 2) prepared in the method of example 2 was added to the reaction mixture in 3 batches, each batch of about 7g, and the addition was completed for about 10 minutes, preventing the addition from being carried out by a vigorous reaction.
After the addition, the reaction is carried out for 10 hours with heat preservation, and the heating is stopped. The reaction solution was cooled to room temperature with stirring, and then cooled to 0 to 10℃with ice water. Suction filtration to remove solids (if necessary with celite filtration). 150ml of 20wt% sodium hydroxide aqueous solution was slowly added dropwise thereto over a period of Bi Jiaoban min. Filtering, removing the generated solid again, and separating filtrate. The aqueous phase was extracted with toluene 50ml×3 times, and the organic layers were combined and dried over anhydrous magnesium sulfate. The drying agent is filtered, and the organic layer is distilled to dryness to obtain orange solid.
The conditions of reducing agent, reaction solvent type and the like are changed to prepare 4-nitro-L-amphetamine alcohol according to the method, and the conditions not related in the table are as follows:
the experimental results show that when tetrahydrofuran, absolute ethyl alcohol and toluene are independently used, the yield of the prepared product is low, the quality is poor, and the product which can be applied to the large-scale production cannot be obtained.
Claims (10)
1. A method for preparing an zolmitriptan intermediate, comprising the steps of:
(1) Taking sulfuric acid aqueous solution as a solvent and concentrated nitric acid or fuming nitric acid as a nitrifying reagent, and performing nitrifying reaction on L-phenylalanine in a microchannel reactor to obtain 4-nitro-L-phenylalanine;
(2) 4-nitro-L-amphetamine is prepared by reduction reaction of 4-nitro-L-phenylalanine in a solvent in the presence of a reducing agent.
2. The process for the preparation of an intermediate of zolmitriptan according to claim 1, wherein in step (1), the process for the preparation of 4-nitro-L-phenylalanine comprises the steps of: dissolving L-phenylalanine in sulfuric acid aqueous solution to obtain L-phenylalanine solution; and respectively and simultaneously introducing the L-phenylalanine solution and concentrated nitric acid or fuming nitric acid into a micro-channel reactor, and performing nitration reaction on the L-phenylalanine to obtain the zolmitriptan intermediate 4-nitro-L-phenylalanine.
3. The process for the preparation of an intermediate of zolmitriptan according to claim 2, wherein the flow rate of the L-phenylalanine solution is 0.5-2ml/min; the flow rate of the concentrated nitric acid or fuming nitric acid is 0.3-1ml/min; preferably, the flow rate of the L-phenylalanine solution is 1ml/min; the flow rate of the concentrated nitric acid or fuming nitric acid is 0.6ml/min.
4. A process for the preparation of an intermediate of zolmitriptan according to claim 1, characterized in that in step (1) it comprises any one of the following conditions:
i. the nitration temperature is-5-30 ℃, preferably 5-20 ℃;
ii. The nitration time is 20 seconds to 300 seconds, preferably 28 seconds to 60 seconds.
5. A process for the preparation of an intermediate of zolmitriptan according to claim 1, wherein in step (2) the solvent consists of solvent a and solvent B;
the solvent A is one or the combination of more than two of tetrahydrofuran, methyltetrahydrofuran, methanol or ethanol; preferably, the solvent A is tetrahydrofuran;
the solvent B is one or the combination of more than two of toluene, dimethylbenzene or dioxane; preferably, the solvent B is toluene;
the volume ratio of the solvent A to the solvent B is 1:0.5-10, preferably 1:1-4.
6. The process for preparing zolmitriptan intermediate according to claim 1, wherein in step (2), the reducing agent is sodium borohydride, potassium borohydride, sodium borohydride-lewis acid, potassium borohydride-iodine, sodium borohydride-H 2 SO 4 Or potassium borohydride-H 2 SO 4 One of them.
7. The process for the preparation of an intermediate of zolmitriptan according to claim 1, wherein in step (2), the molar ratio of 4-nitro-L-phenylalanine to reducing agent is 1:1-8.
8. The process for preparing an intermediate of zolmitriptan according to claim 5, wherein in step (2), the solvent A and the solvent B are added before the addition of 4-nitro-L-phenylalanine, or the solvent A is added before the addition of 4-nitro-L-phenylalanine and the solvent B is added after the addition of 4-nitro-L-phenylalanine.
9. The process for the preparation of an intermediate of zolmitriptan according to claim 1, wherein in step (2), the process for the preparation of an intermediate of zolmitriptan comprises the steps of:
adding a reducing agent and 4-nitro-L-phenylalanine into the solvent A; then adding a solvent B, and reacting to obtain an zolmitriptan intermediate 4-nitro-L-amphetamine alcohol;
or, adding a reducing agent into the solvent A, and adding 4-nitro-L-phenylalanine in batches; then adding a solvent B, and reacting to obtain the zolmitriptan intermediate 4-nitro-L-amphetamine.
10. A process for the preparation of an intermediate of zolmitriptan according to claim 9, comprising any one of the following conditions:
i. the step of heating and refluxing is further included after the reducing agent and the 4-nitro-L-phenylalanine are added into the solvent A;
ii. The method can also comprise the step of heating and refluxing before adding the 4-nitro-L-phenylalanine in batches; alternatively, the method may further comprise a step of heating and refluxing after the 4-nitro-L-phenylalanine is added in portions;
iii, the reaction temperature after adding the solvent B is 66-140 ℃, preferably 80-100 ℃; the reaction time is 2 to 24 hours, preferably 6 to 12 hours;
iv, when 4-nitro-L-phenylalanine is added in batches, the addition is carried out in batches of 2-4 and the addition is completed in 5-15 minutes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310613940.7A CN116574014A (en) | 2023-05-25 | 2023-05-25 | Preparation method of zolmitriptan intermediate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310613940.7A CN116574014A (en) | 2023-05-25 | 2023-05-25 | Preparation method of zolmitriptan intermediate |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116574014A true CN116574014A (en) | 2023-08-11 |
Family
ID=87542990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310613940.7A Pending CN116574014A (en) | 2023-05-25 | 2023-05-25 | Preparation method of zolmitriptan intermediate |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116574014A (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1950388A (en) * | 2004-02-27 | 2007-04-18 | 瑞伯-X医药品有限公司 | Macrocyclic compounds and methods of making and using the same |
WO2008106226A2 (en) * | 2007-02-28 | 2008-09-04 | Rib-X Pharmaceuticals, Inc. | Macrolide compounds and methods of making and using the same |
CN101693710A (en) * | 2009-10-19 | 2010-04-14 | 苏州市立德化学有限公司 | Method for preparing Zolmitriptan |
CN103275075A (en) * | 2013-06-24 | 2013-09-04 | 成都天台山制药有限公司 | Zolmitriptan and preparation method thereof |
CN109963839A (en) * | 2016-09-19 | 2019-07-02 | 香港理工大学 | Chiral cycleanine compound and application thereof |
-
2023
- 2023-05-25 CN CN202310613940.7A patent/CN116574014A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1950388A (en) * | 2004-02-27 | 2007-04-18 | 瑞伯-X医药品有限公司 | Macrocyclic compounds and methods of making and using the same |
WO2008106226A2 (en) * | 2007-02-28 | 2008-09-04 | Rib-X Pharmaceuticals, Inc. | Macrolide compounds and methods of making and using the same |
CN101693710A (en) * | 2009-10-19 | 2010-04-14 | 苏州市立德化学有限公司 | Method for preparing Zolmitriptan |
CN103275075A (en) * | 2013-06-24 | 2013-09-04 | 成都天台山制药有限公司 | Zolmitriptan and preparation method thereof |
CN109963839A (en) * | 2016-09-19 | 2019-07-02 | 香港理工大学 | Chiral cycleanine compound and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108440330B (en) | Preparation method of doxycycline hydrochloride | |
CN111253218A (en) | Synthesis method and device of 2,3, 5-trimethylhydroquinone | |
CN113024385B (en) | Preparation method of 2,2 '-bis (trifluoromethyl) -4, 4' -diaminobiphenyl | |
CN114380741A (en) | Preparation method of 4-position alkylated derivative of 2-methylquinoline compound | |
CN116574014A (en) | Preparation method of zolmitriptan intermediate | |
CN115232013B (en) | Preparation method of aromatic amine compound | |
CN114057588B (en) | Synthesis method of 8-amino-2-naphthol | |
CN112110803B (en) | Preparation method of 3',5' -dichloro-2, 2, 2-trifluoro acetophenone | |
JP2984047B2 (en) | Method for producing 1-amino-4-alkoxybenzenes | |
CN111170837B (en) | Synthesis method of methyl ketone compound | |
CN109438374B (en) | Continuous synthesis method of rufinamide | |
CN112300151B (en) | Preparation method of milpitant intermediate | |
KR100707050B1 (en) | Method of preparing 10H-Dibenzo[b,f][1,4]thiazepine-11-one | |
CN112920060A (en) | Synthesis device and application of 2, 6-dichloro-4-aminophenol | |
WO2022061920A1 (en) | Method for preparing 3',5'-dichloro-2,2,2-trifluoroacetophenone | |
CN114349660B (en) | Synthesis method of o-chlorobenzonitrile | |
CN111763149A (en) | Preparation method of phenylenediamine and phenylenediamine inorganic salt | |
CN114394908B (en) | Method for preparing 2-hydroxy-3-aminoacetophenone | |
KR100711310B1 (en) | Process for the preparation of benzidine compound | |
CN113412255B (en) | Process for preparing 4-amino-5-methylpyridinone | |
CN115974809B (en) | Method for preparing benzo [ d ] isothiazolin-3 (2H) -ketone through oxygen transfer reaction | |
CN115677559B (en) | One-step synthesis method of ondansetron intermediate tetrahydrocarbazolone | |
CN109776403B (en) | Method for preparing 1-tert-butyloxycarbonyl-4- [3- (alkylamino) -2-pyridyl ] piperazine | |
CN111574477B (en) | Synthesis method of amide compound | |
KR20020095771A (en) | Process for the preparation of benzidine compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |